DOCSLIB.ORG

ANTIMICROBIAL AGENTS and CHEMOTHERAPY Volume 30 September 1986 No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANTIMICROBIAL AGENTS and CHEMOTHERAPY Volume 30 September 1986 No ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Volume 30 September 1986 No. 3 MINIREVIEW In Vitro and Pharmacokinetic Properties of the Carbapenems. Richard Wise ... 343-349 CHEMISTRY: BIOSYNTHESIS Synthesis and Antimicrobial Activity of a Series of Caespitin Derivatives. Cornelis J. Van der Schyf, Theodor G. Dekker, Theunis G. Fourie, and Friedrich 0. Snyckers ................................................ 375-381 Antifungal Macrodiolide from Streptomyces sp. H. R. Y. Jois, Annapoorna Sarkar, and S. Gurusiddaiah ........... ............................... 458-464 MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS Effect of Antibiotics on Adherence of Haemophilus influenzae Type b. Janet R. Gilsdorf and Jill M. Jesperson ......................................... 370-374 Aryl-Fluoroquinolone Derivatives A-56619 (Difloxacin) and A-56620 Inhibit Mito- gen-Induced Human Mononuclear Cell Proliferation. Sastry V. S. Gollapudi, Bharathi Vayuvegula, Sudhir Gupta, Michael Fok, and Haragopal Thadepalli ................................................. 390-394 Membrane Perturbation by Aminoglycosides as a Simple Screen of Their Toxicity. Stacley Au, Norman Weiner, and Jochen Schacht ....................... 395-397 Astromicin-Induced Membrane Damage in Serratia marcescens. Akiko Umeda, Kunihiko Murata, and Kazunobu Amako .............................. 398-402 Novel Morphological Changes in Gram-Negative Bacteria Caused by Combination of Bulgecin and Cefmenoxime. Masafumi Nakao, Koichi Yukishige, Masahiro Kondo, and Akira Imada .................................... 414-417 7at-Formylamino Substituent Confers P-Lactamase-Inactivating Potency on 1-Oxacephalosporins. Kazuhisa Murakami, Masayoshi Doi, and Tadashi Yoshida ............................................................ 447-452 Inhibition of DNA Replication Initiation by Aminoglycoside Antibiotics. Keita Matsunaga, Hiroshi Yamaki, Toshio Nishimura, and Nobuo Tanaka ...... 468-474 Influence of jI-Lactam Antibiotics and Ciprofloxacin on Composition and Immu- nogenicity of Escherichia coli Outer Membrane. Hermann Leying, Sebastian Suerbaum, Hein-Peter Kroll, Helge Karch, and Wolfgang Opferkuch .......................................................... 475-480 Allium sativum (Garlic) Inhibits Lipid Synthesis by Candida albicans. Moses Adetumbi, George T. Javor, and Benjamin H. S. Lau ...... ............. 499-501 MECHANISMS OF RESISTANCE Evidence for Multiple Forms of Type I Chromosomal P-Lactamase in Pseudo- monas aeruginosa. Mark L. Gates, Christine C. Sanders, Richard V. Goering, and W. Eugene Sanders, Jr................................... 453-457 Mutation within the Herpes Simplex Virus DNA Polymerase Gene Conferring Resistance to (R)-9-(3,4-Dihydroxybutyl)Guanine. Henry C. Chiou, Kelvin M. Kerns, and Donald M. Coen ................................ 502-504 Continued on following page Continued from preceding page Characterization of a,-Lactamase-Specifying Plasmid Isolated from Eikenella corrodens and Its Relationship to a Commensal Neisseria Plasmid. Rafael Rotger, Elena Garcia-Valdes, and Emilio Perez Trallero... .............. 508-509 SUSCEPTIBILITY In Vitro Activity andP-Lactamase Stability of Two Oral Cephalosporins, Cefte- trame (Ro 19-5247) and Cefetamet (Ro 15-8074). Harold C. Neu, Nai-Xun Chin, and Pornpen Labthavikul...... ................................. 423-428 In Vitro Activities of Ro 19-5247 and Ro 15-8074, New Oral Cephalosporins. Robert J. Fass and Valerie L. Helsel.................................. 429-434 Susceptibility of Campylobacter pyloridis to 20 Antimicrobial Agents. Thierry Lambert, Francis Megraud, Guy Gerbaud, and Patrice Courvalin ......... 510-511 In Vitro Activities of U-63366, a Spectinomycin Analog; Roxithromycin (RU 28965), a New Macrolide Antibiotic; and Five Quinolone Derivatives against Haemophilus ducreyi. Marie-Jose Sanson-Le Pors, Isabelle M. Casin, Marie-Christine Thebault, Guillaume Arlet, and Yvonne Perol ............ 512-513 In Vitro Antiviral Activity of the 6-Substituted 2-(3',4'-Dichlorophenoxy)-2H- Pyrano[2,3-b]Pyridines MDL 20,610, MDL 20,646, and MDL 20,957. Michael T. Kenny, Jacqueline K. Dulworth, Thomas M. Bargar, Harry L. Torney, Michael C. Graham, and A. M. Manelli ........................ 516-518 EXPERIMENTAL THERAPEUTICS Activity of SM-4470, a New Imidazole Derivative, against Experimental Fungal Infections. Katsuaki Ichise, Tomoharu Tanio, Ikutaro Saji, and Takao Okuda .............................................................. 366-369 Efficacy of Ciprofloxacin for Experimental Endocarditis Caused by Methicillin- Susceptible or -Resistant Strains of Staphylococcus aureus. T. C. Carpenter, C. J. Hackbarth, H. F. Chambers, and M. A. Sande .... ................ 382-384 Continuous Versus Intermittent Administration of Ceftazidime in Experimental Klebsiella pneumoniae Pneumonia in Normal and Leukopenic Rats. Robert Roosendaal, Irma A. J. M. Bakker-Woudenberg, Marion van den Berghe- van Raffe, and Marc F. Michel ........................................ 403-408 Suppression of Scrapie Infection in Mice by Heteropolyanion 23, Dextran Sulfate, and Some Other Polyanions. Richard H. Kimberlin and Carol A. Walker 409-413 Activity of Fluconazole (UK 49,858) and Ketoconazole against Candida albicans In Vitro and In Vivo. Thomas E. Rogers and John N. Galgiani ............. 418-422 Antimicrobial Therapy of Experimental Endocarditis Caused by Nutritionally Variant Viridans Group Streptococci. Nancy K. Henry, Walter R. Wilson, Richard B. Roberts, Jacques F. Acar, and Joseph E. Geraci .... ......... 465-467 Delayed Treatment with Combinations of Antiviral Drugs in Mice Infected with Herpes Simplex Virus and Application of the Median Effect Method of Analysis. Raymond F. Schinazi, Ting-Chao Chou, Robert Taylor Scott, Xuejun Yao, and Andre J. Nahmias ................................... 491-498 CLINICAL THERAPEUTICS Comparison of Cyclacillin and Amoxicillin for Therapy of Acute Maxillary Sinus- itis. W. Michael Scheld, Austin Sydnor, Jr., Barry Farr, Jean C. Gratz, and Jack M. Gwaltney, Jr............................................. 350-353 Clinical Comparison of Piperacillin and Cefoxitin in Patients with Bacteriologic- ally Confirmed Infections. Richard V. McCloskey ...... ................ 354-358 Continued on following page Continuedfrom preceding page Antibiotic-Resistant Bacteria in Surveillance Stool Cultures of Patients with Pro- longed Neutropenia. John R. Wingard, James Dick, Patricia Charache, and Rein Saral ....................................................... 435-439 Norfioxacin in the Therapy of Uncomplicated Gonorrhea. Barbara Romanowski, Helen Wood, Jean Draker, and Michael C. Tsianco ........ 514-515 PHARMACOLOGY Comparative Pharmacokinetics of Low- and High-Dose Ticarcillin. B. Joseph Guglielmo, John F. Flaherty, Robert Batman, Steven L. Barriere, and John G. Gambertoglio ................................................ 359-360 New Sodium Hydroxide Digestion Method for Measurement of Renal Tobramycin Concentrations. David N. Gilbert and Sue J. Kohlhepp ..... ............ 361-365 Renal Cortical Kinetics of Gentamicin after Implantation of Gentamicin-Poly- methylmethacrylate Beads in Rats. Ruben A. Giuliano, Gert A. Verpooten, and Marc E. De Broe ......... ............................ 385-389 Dose Ranging Study and Constant Infusion Evaluation of Ciprofloxacin. George L. Drusano, Karen I. Plaisance, Alan Forrest, and Harold C. Standiford 440-443 Absolute Oral Bioavailability of Ciprofloxacin. George L. Drusano, Harold C. Standiford, Karen Plaisance, Alan Forrest, James Leslie, and James Caldwell ............................................................ 444-446 Penetration of Amoxicillin and Potassium Clavulanate into the Cerebrospinal Fluid of Patients with Inflamed Meninges. Johan S. Bakken, Johan N. Bruun, Peter Gaustad, and Timothy C. G. Tasker ....................... 481-484 Pharmacokinetics of Cefixime (CL 284,635; FK 027) in Healthy Subjects and Patients with Renal Insufficiency. D. R. P. Guay, R. C. Meatherall, G. K. Harding, and G. R. Brown...................................... 485-490 Aztreonam Concentrations in Human Tissues Obtained During Thoracic and Gynecologic Surgery. T. R. Beam, Jr., R. P. Galask, L. T. Friedhoff, T. B. Platt, and M. A. Leitz ........... ............................... 505-507 ERRATUM Comparative Single-Dose Pharmacokinetics of Amantadine Hydrochloride and Rimantadine Hydrochloride in Young and Elderly Adults. Frederick G. Hayden, Anil Minocha, Daniel A. Spyker, and Howard E. Hoffman ...... 519 Date of Issue: 10 September 1986 CHANGE IN METHOD OF DELIVERY FOR SUBSCRIPTIONS OUTSIDE THE UNITED STATES For the past several years, ASM journal subscriptions have been fulfilled via air drop shipment to central distribution points, from which the issues were then mailed. Unfortunately, we can no longer afford this service. To hold down drastically rising costs, we have arranged to distribute our journals through surface drop shipment followed by mailing. Subscribers outside the United States will receive their issues two to three weeks later than heretofore, for which we are deeply regretful. There was no way that we could continue the previous service at its very expensive and continually increasing cost. This change in mode of delivery will be effective beginning with the November issues. Subscribers within the United States and subscribers from abroad who are paying the surcharge for direct air mail shipment will be unaffected by the change..
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Performance Standards for Antimicrobial Susceptibility Testing
    26th Edition M100S Performance Standards for Antimicrobial Susceptibility Testing This document provides updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02-A12, M07-A10, and M11-A8. An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process. Licensedto:Landspitali-NationalUniversityHospital-DivisionofDiagnosticMedicine Thisdocumentisprotectedbycopyright.CLSIorder#0,Downloadedon12/28/2015. Clinical and Laboratory Standards Institute Setting the standard for quality in medical laboratory testing around the world. The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability. Consensus Process Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement. Commenting on Documents CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care. CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.
    [Show full text]
  • Breakpoints Eliminated from CLSI Document M100 Since 2010
    Breakpoints Eliminated from CLSI document M100 Since 2010 Interpretive Categories and Zone Diameter Breakpoints, Interpretive Categories and M100 Edition in Which Antimicrobial Disk nearest whole mm MIC Breakpoints, µg/mL Breakpoints Were Last Agent Content S I R S I R Included/Comments Rationale Enterobacteriaceae Cephalothin 30 µg ≥ 18 15–17 ≤ 14 ≤ 8 16 ≥ 32 M100-S25 Cefazolin is a more reliable surrogate than cephalothin (surrogate test for for predicting results for oral cephalosporins that uncomplicated UTI) might be used for treatment of uncomplicated UTIs. Nalidixic acid 30 µg ≥ 19 14–18 ≤ 13 ≤ 16 – ≥ 32 M100S, 26th ed. Nalidixic acid does not perform reliably in predicting Deleted for Salmonella spp. only susceptibility to fluoroquinolones that might be used for treatment of Salmonella infections. It has been shown to produce both false-resistant and false- susceptible results.1,2 Norfloxacin 10 µg ≥ 17 13–16 ≤ 12 ≤ 4 8 ≥ 16 M100, 28th ed. This agent is no longer available. Ticarcillin 75 µg ≥ 20 15–19 ≤ 14 ≤ 16 32–64 ≥ 128 M100-S25 This agent is no longer available. Pseudomonas aeruginosa Cefoperazone 75 µg ≥ 21 16–20 ≤ 15 ≤ 16 32 ≥ 64 M100-S20 These agents are no longer available or have limited Cefotaxime 30 µg ≥ 23 15–22 ≤ 14 ≤ 8 16–32 ≥ 64 M100-S20 indications for P. aeruginosa. Ceftizoxime 30 µg ≥ 20 15–19 ≤ 14 ≤ 8 16–32 ≥ 64 M100-S20 Ceftriaxone 30 µg ≥ 21 14–20 ≤ 13 ≤ 8 16–32 ≥ 64 M100-S20 Moxalactam 30 µg ≥ 23 15–22 ≤ 14 ≤ 8 16–32 ≥ 64 M100-S20 Norfloxacin 10 µg ≥ 17 13–16 ≤ 12 ≤ 4 8 ≥ 16 M100, 28th ed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom Et Al
    USOO8383154B2 (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom et al. (45) Date of Patent: Feb. 26, 2013 (54) SWELLABLE DOSAGE FORM COMPRISING W W 2.3. A. 3. 2. GELLAN GUMI WO WOO1,76610 10, 2001 WO WOO2,46571 A2 6, 2002 (75) Inventors: Daniel Bar-Shalom, Kokkedal (DK); WO WO O2/49571 A2 6, 2002 Lillian Slot, Virum (DK); Gina Fischer, WO WO 03/043638 A1 5, 2003 yerlosea (DK), Pernille Heyrup WO WO 2004/096906 A1 11, 2004 Hemmingsen, Bagsvaerd (DK) WO WO 2005/007074 1, 2005 WO WO 2005/007074 A 1, 2005 (73) Assignee: Egalet A/S, Vaerlose (DK) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 JECFA, “Gellangum”. FNP 52 Addendum 4 (1996).* U.S.C. 154(b) by 1259 days. JECFA, “Talc”, FNP 52 Addendum 1 (1992).* Alterna LLC, “ElixSure, Allergy Formula', description and label (21) Appl. No.: 111596,123 directions, online (Feb. 6, 2007). Hagerström, H., “Polymer gels as pharmaceutical dosage forms'. (22) PCT Filed: May 11, 2005 comprehensive Summaries of Uppsala dissertations from the faculty of pharmacy, vol. 293 Uppsala (2003). (86). PCT No.: PCT/DK2OOS/OOO317 Lin, “Gellan Gum', U.S. Food and Drug Administration, www. inchem.org, online (Jan. 17, 2005). S371 (c)(1), Miyazaki, S., et al., “In situ-gelling gellan formulations as vehicles (2), (4) Date: Aug. 14, 2007 for oral drug delivery”. J. Control Release, vol. 60, pp. 287-295 (1999). (87) PCT Pub. No.: WO2005/107713 Rowe, Raymond C.
    [Show full text]
  • Antibiotic Classes
    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]